[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider sale to cover tax withholding on vested RSUs. Dr. Barry Ticho, Chief Medical Officer of Stoke Therapeutics (STOK), disposed of 2,805 shares of common stock in an issuer-mandated sale to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units. The reported weighted-average sale price was $18.238 per share, with individual sale prices ranging from $18.00 to $18.50 per share. After the reported disposition, Dr. Ticho beneficially owns 23,970 shares directly.

This Form 4 reports a routine, non-discretionary sale related to compensation tax withholding rather than an open-market decision to divest additional holdings.

Insights

Corporate Governance Expert

TL;DR: Routine issuer-mandated sale of vested RSUs to satisfy tax obligations; not an unusual governance signal.

The transaction is explicitly described as an issuer-mandated sale to cover tax withholding on restricted stock unit vesting, which typically reflects standard compensation mechanics rather than a deliberate market sale by the executive. The weighted-average price and the disclosed range support transparency about execution. The post-transaction beneficial ownership of 23,970 shares remains disclosed, preserving public visibility into insider holdings.

Securities Analyst

TL;DR: Non-discretionary sale; limited informational value for valuation or operational outlook.

From a securities perspective, the sale size (2,805 shares) and characterization as tax-withholding indicate limited informational content regarding company performance or insider sentiment. The disclosed price range ($18.00 to $18.50) and weighted-average price ($18.238) provide execution context but do not alter material financial metrics for the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S(1)		2,805	D	$18.238(2)	23,970	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Stoke Therapeutics insider Barry Ticho do in the reported Form 4?

The Chief Medical Officer disposed of 2,805 shares in an issuer-mandated sale to satisfy tax withholding from vested restricted stock units.

At what price were the shares sold by the STOK insider?

The reported weighted-average sale price was $18.238 per share; individual sale prices ranged from $18.00 to $18.50 per share.

How many STOK shares does Barry Ticho own after the sale?

Following the reported transaction, he beneficially owns 23,970 shares directly.

Was the insider sale discretionary or mandated?

The filing states the sale was an issuer-mandated sale to satisfy tax withholding on RSU vesting.

Does this Form 4 disclose derivative transactions or option exercises?

No; the filing reports only a non-derivative disposition of common stock and states the sale related to RSU withholding.